Published in Int J Oncol on February 06, 2013
A stem cell medium containing neural stimulating factor induces a pancreatic cancer stem-like cell-enriched population. Int J Oncol (2014) 0.82
The Id-protein family in developmental and cancer-associated pathways. Cell Commun Signal (2017) 0.78
Gene expression and pathway analysis of CTNNB1 in cancer and stem cells. World J Stem Cells (2016) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell (1990) 15.36
Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet (2002) 7.67
Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13
Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature (1999) 6.50
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
ID helix-loop-helix proteins in cell growth, differentiation and tumorigenesis. J Cell Sci (2000) 3.85
Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol (2005) 3.66
Focus on hepatocellular carcinoma. Cancer Cell (2004) 3.49
Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev (1999) 3.22
Cyclin-binding motifs are essential for the function of p21CIP1. Mol Cell Biol (1996) 2.83
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol (2011) 2.28
Histone acetylation and disease. Cell Mol Life Sci (2001) 2.11
Id-related genes encoding helix-loop-helix proteins are required for G1 progression and are repressed in senescent human fibroblasts. J Biol Chem (1994) 2.09
Consequences of heteromeric interactions among helix-loop-helix proteins. Cell Growth Differ (1993) 1.90
Id proteins in cell cycle control and cellular senescence. Oncogene (2001) 1.88
A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res (2000) 1.83
The Id proteins and angiogenesis. Oncogene (2001) 1.70
Targeting histone deacetylase in cancer therapy. Med Res Rev (2006) 1.69
Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 1.62
Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev (2006) 1.57
Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol (2004) 1.55
A human Id-like helix-loop-helix protein expressed during early development. Proc Natl Acad Sci U S A (1992) 1.53
Id-1 and Id-2 proteins as molecular markers for human prostate cancer progression. Clin Cancer Res (2004) 1.33
Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol (1999) 1.33
Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index. Cancer Res (2001) 1.33
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res (2003) 1.32
Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB. Oncogene (2004) 1.31
Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res (2000) 1.28
Epigenetic inactivation of ID4 in colorectal carcinomas correlates with poor differentiation and unfavorable prognosis. Clin Cancer Res (2004) 1.25
Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer. Oncogene (2005) 1.24
Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. Cancer Res (2003) 1.21
Id proteins are dynamically expressed in normal epidermis and dysregulated in squamous cell carcinoma. Cancer Res (2000) 1.21
Mutually exclusive expression of a helix-loop-helix gene and N-myc in human neuroblastomas and in normal development. EMBO J (1992) 1.16
Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol (2008) 1.16
Identification of genes up-regulated by histone deacetylase inhibition with cDNA microarray and exploration of epigenetic alterations on hepatoma cells. J Hepatol (2004) 1.13
The regulation and function of the Id proteins in lymphocyte development. Oncogene (2001) 1.11
Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem (2001) 1.08
Id gene expression as a key mediator of tumor cell biology. Cancer Res (1999) 1.07
Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res (2008) 1.05
Mule determines the apoptotic response to HDAC inhibitors by targeted ubiquitination and destruction of HDAC2. Genes Dev (2011) 1.03
Regulation of angiogenesis by Id-1 through hypoxia-inducible factor-1alpha-mediated vascular endothelial growth factor up-regulation in hepatocellular carcinoma. Clin Cancer Res (2006) 1.02
High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells. Int J Cancer (2005) 1.00
A role for Id proteins in mammary gland physiology and tumorigenesis. Adv Cancer Res (2004) 0.97
Expression of Id proteins in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Int J Oncol (2005) 0.96
Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett (2005) 0.85
The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int J Oncol (2010) 0.85
Overexpressed Id-1 is associated with a high risk of hepatocellular carcinoma development in patients with cirrhosis without transcriptional repression of p16. Cancer (2005) 0.83
Identification of ID2 associated with invasion of hepatitis C virus-related hepatocellular carcinoma by gene expression profile. Int J Oncol (2006) 0.81
Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet (2003) 3.93
Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res (2002) 1.64
A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. Proteome Sci (2013) 1.44
Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia (2008) 1.28
Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol (2008) 1.26
Simple genotype analysis of the Asp299Gly polymorphism of the Toll-like receptor-4 gene that is associated with lipopolysaccharide hyporesponsiveness. J Clin Lab Anal (2002) 1.23
Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol (2007) 1.22
Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis. Proteomics (2005) 1.20
Gene expression profile linked to p53 status in hepatitis C virus-related hepatocellular carcinoma. FEBS Lett (2003) 1.15
Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH. Mod Pathol (2004) 1.15
Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer (2009) 1.14
Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer (2002) 1.12
TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer (2010) 1.10
Expression of estrogen receptor-alpha and -beta mRNAs in human gastric cancer. Cancer Lett (2002) 1.10
Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics (2003) 1.07
Increased expression of MUC1 in advanced pancreatic cancer. J Gastroenterol (2003) 1.06
Decreased ID2 promotes metastatic potentials of hepatocellular carcinoma by altering secretion of vascular endothelial growth factor. Clin Cancer Res (2008) 1.05
Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes. Anticancer Res (2008) 1.04
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Integrin alpha2 mediates selective metastasis to the liver. Cancer Res (2009) 1.03
Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery (2004) 1.03
Anticachectic effects of the natural herb Coptidis rhizoma and berberine on mice bearing colon 26/clone 20 adenocarcinoma. Int J Cancer (2002) 1.02
Proteomic profiling of proteins decreased in hepatocellular carcinoma from patients infected with hepatitis C virus. Proteomics (2004) 1.00
A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J Transl Med (2014) 0.99
Impact of surgical site infection after colorectal surgery on hospital stay and medical expenditure in Japan. Surg Today (2012) 0.99
Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. Cancer Res (2002) 0.98
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics (2006) 0.98
Differential gene expression in distinct virologic types of hepatocellular carcinoma: association with liver cirrhosis. Oncogene (2003) 0.97
MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res (2005) 0.96
Breast sentinel lymph node mapping at CT lymphography with iopamidol: preliminary experience. Radiology (2003) 0.96
Patterns of expression of cytochrome P450 genes in progression of hepatitis C virus-associated hepatocellular carcinoma. Int J Oncol (2005) 0.96
Lymphatic drainage from esophagogastric tract: feasibility of endoscopic CT lymphography for direct visualization of pathways. Radiology (2005) 0.96
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. BMC Res Notes (2012) 0.96
A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J Transl Med (2014) 0.96
Predicting individual outcomes in hepatocellular carcinoma. Lancet (2004) 0.95
Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Sci (2009) 0.95
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res (2012) 0.94
Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics (2005) 0.93
A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study. J Pathol (2009) 0.92
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer. J Immunother (2014) 0.92
Gain of 5p15 detected by comparative genomic hybridization as an independent marker of poor prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res (2002) 0.92
Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis. Cancer Genet Cytogenet (2003) 0.92
Translational microarray systems for outcome prediction of hepatocellular carcinoma. Cancer Sci (2008) 0.92
Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer. Int J Cancer (2002) 0.92
Facilitation of adenoviral wild-type p53-induced apoptotic cell death by overexpression of p33(ING1) in T.Tn human esophageal carcinoma cells. Oncogene (2002) 0.92
Increased prevalence of regulatory T-cells in the peripheral blood of patients with gastrointestinal cancer. Anticancer Res (2009) 0.92
Imbalance in expression levels of insulin-like growth factor 2 and H19 transcripts linked to progression of hepatocellular carcinoma. Anticancer Res (2005) 0.91
Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma. Int J Cancer (2005) 0.91
The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues. Jpn J Clin Oncol (2010) 0.90
The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery. J Hepatobiliary Pancreat Surg (2009) 0.90
Classification of biliary tract cancers established by the Japanese Society of Hepato-Biliary-Pancreatic Surgery: 3(rd) English edition. J Hepatobiliary Pancreat Sci (2015) 0.90
Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol (2006) 0.89
Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search. Int J Oncol (2008) 0.89
High serum levels of vascular endothelial growth factor after hepatectomy are associated with poor prognosis in hepatocellular carcinoma. Hepatogastroenterology (2009) 0.89
Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy. Oncol Rep (2006) 0.89
Photon pair generation in a silicon micro-ring resonator with reverse bias enhancement. Opt Express (2013) 0.89
Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer (2014) 0.89
Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. Oncol Rep (2008) 0.89
Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma. Anticancer Res (2007) 0.88
Molecular signature in three types of hepatocellular carcinoma with different viral origin by oligonucleotide microarray. Int J Oncol (2004) 0.88
CT lymphography-navigated sentinel lymph node biopsy in patients with superficial esophageal cancer. Surgery (2006) 0.88
Identification of common or distinct genes related to antitumor activities of a medicinal herb and its major component by oligonucleotide microarray. Int J Cancer (2003) 0.88
Prospective ultrasonographic prediction of sentinel lymph node metastasis by real-time virtual sonography constructed with three-dimensional computed tomography-lymphography in breast cancer patients. Breast Cancer (2011) 0.87
Proteomic differential display analysis shows up-regulation of 14-3-3 sigma protein in human scirrhous-type gastric carcinoma cells. Anticancer Res (2010) 0.87
Length of stay and cost for surgical site infection after abdominal and cardiac surgery in Japanese hospitals: multi-center surveillance. Surg Infect (Larchmt) (2012) 0.86
Relation between serum levels of cell-free DNA and inflammation status in hepatitis C virus-related hepatocellular carcinoma. Oncol Rep (2008) 0.86
Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers. Clin Chim Acta (2010) 0.86
Differential expression of up-regulated cofilin-1 and down-regulated cofilin-2 characteristic of pancreatic cancer tissues. Oncol Rep (2011) 0.86
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Sci (2013) 0.86
[Immunoregulatory effects of PSK on the Th1/Th2 balance and regulatory T-cells in patients with colorectal cancer]. Gan To Kagaku Ryoho (2010) 0.86
Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res (2009) 0.86
Self-organizing-map-based molecular signature representing the development of hepatocellular carcinoma. FEBS Lett (2005) 0.85
Current antibiotic prophylaxis in pancreatoduodenectomy in Japan. J Hepatobiliary Pancreat Surg (2005) 0.85
Improvement of early delayed gastric emptying in patients with Billroth I type of reconstruction after pylorus preserving pancreatoduodenectomy. J Hepatobiliary Pancreat Surg (2009) 0.85
The assessment of methylated BASP1 and SRD5A2 levels in the detection of early hepatocellular carcinoma. Int J Oncol (2010) 0.85
Breast sentinel lymph node navigation with three-dimensional interstitial multidetector-row computed tomographic lymphography. Invest Radiol (2005) 0.85
Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis (2009) 0.85
Germline copy number variations associated with breast cancer susceptibility in a Japanese population. Tumour Biol (2012) 0.85
Molecular features linked to the growth-inhibitory effects of gemcitabine on human pancreatic cancer cells. Oncol Rep (2006) 0.84
Esophageal squamous cell carcinomas with distinct invasive depth show different gene expression profiles associated with lymph node metastasis. Int J Oncol (2006) 0.84
Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma. Oncol Rep (2006) 0.84